Which has preferable earnings & valuation, BRUN or ALP?

Boost Run has higher revenue and earnings than Portage Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boost Run $56.42M N/A N/A N/A N/A Portage Biotech $100K 23.28 -$38.63M -$8.18 N/A

Is BRUN or ALP more profitable?

Company Net Margins Return on Equity Return on Assets Boost Run N/A N/A N/A Portage Biotech N/A N/A N/A

Do analysts recommend ALP or ALIS?

Portage Biotech currently has a consensus price target of $0.25, indicating a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Portage Biotech is more favorable than Calisa Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Calisa Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ALP or ALIS?

Calisa Acquisition has lower revenue, but higher earnings than Portage Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Portage Biotech $100K 23.28 -$38.63M -$8.18 N/A Calisa Acquisition N/A N/A N/A N/A N/A

Is ALP or ALIS more profitable?

Company Net Margins Return on Equity Return on Assets Portage Biotech N/A N/A N/A Calisa Acquisition N/A N/A N/A

Do analysts rate ALP or CORZZ?

Portage Biotech currently has a consensus target price of $0.25, indicating a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Portage Biotech is more favorable than Core Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Core Scientific 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ALP or CORZZ?

Core Scientific has higher revenue and earnings than Portage Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Portage Biotech $100K 23.28 -$38.63M -$8.18 N/A Core Scientific $440.31M N/A N/A N/A N/A

Is ALP or CORZZ more profitable?

Company Net Margins Return on Equity Return on Assets Portage Biotech N/A N/A N/A Core Scientific N/A N/A N/A

Do analysts rate ALP or CORZW?

Portage Biotech presently has a consensus price target of $0.25, indicating a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Portage Biotech is more favorable than Core Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Core Scientific 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, ALP or CORZW?

Core Scientific has higher revenue and earnings than Portage Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Portage Biotech $100K 23.28 -$38.63M -$8.18 N/A Core Scientific $440.31M N/A N/A N/A N/A

Is ALP or CORZW more profitable?

Company Net Margins Return on Equity Return on Assets Portage Biotech N/A N/A N/A Core Scientific N/A N/A N/A

Do analysts rate BCARW or ALP?

Portage Biotech has a consensus price target of $0.25, suggesting a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Portage Biotech is more favorable than D. Boral ARC Acquisition I. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score D. Boral ARC Acquisition I 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Portage Biotech 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable earnings and valuation, BCARW or ALP?

D. Boral ARC Acquisition I has higher earnings, but lower revenue than Portage Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio D. Boral ARC Acquisition I N/A N/A N/A N/A N/A Portage Biotech $100K 23.28 -$38.63M -$8.18 N/A

Is BCARW or ALP more profitable?

Company Net Margins Return on Equity Return on Assets D. Boral ARC Acquisition I N/A N/A N/A Portage Biotech N/A N/A N/A

Portage Biotech (ALP) Competitors

$0.10 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

ALP vs. BRUN, ALIS, CORZZ, CORZW, and BCARW

Should you buy Portage Biotech stock or one of its competitors? Portage Biotech's main competitors and comparable companies include Boost Run (BRUN), Calisa Acquisition (ALIS), Core Scientific (CORZZ), Core Scientific (CORZW), and D. Boral ARC Acquisition I (BCARW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "internet services & infrastructure" industry.

How does Portage Biotech compare to Boost Run?

Boost Run (NASDAQ:BRUN) and Portage Biotech (NASDAQ:ALP) are both technology companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Boost Run presently has a consensus target price of $45.00, suggesting a potential upside of 155.10%. Portage Biotech has a consensus target price of $0.25, suggesting a potential upside of 152.02%. Given Boost Run's stronger consensus rating and higher possible upside, research analysts plainly believe Boost Run is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boost Run	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Portage Biotech	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Company	Net Margins	Return on Equity	Return on Assets
Boost Run	N/A	N/A	N/A
Portage Biotech	N/A	N/A	N/A

In the previous week, Portage Biotech had 2 more articles in the media than Boost Run. MarketBeat recorded 2 mentions for Portage Biotech and 0 mentions for Boost Run. Boost Run's average media sentiment score of 0.00 equaled Portage Biotech'saverage media sentiment score.

Company	Overall Sentiment
Boost Run	Neutral
Portage Biotech	Neutral

Boost Run has higher revenue and earnings than Portage Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boost Run	$56.42M	N/A	N/A	N/A	N/A
Portage Biotech	$100K	23.28	-$38.63M	-$8.18	N/A

13.4% of Portage Biotech shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Boost Run beats Portage Biotech on 4 of the 6 factors compared between the two stocks.

How does Portage Biotech compare to Calisa Acquisition?

Portage Biotech (NASDAQ:ALP) and Calisa Acquisition (NASDAQ:ALIS) are both technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Calisa Acquisition	N/A	N/A	N/A

In the previous week, Portage Biotech had 2 more articles in the media than Calisa Acquisition. MarketBeat recorded 2 mentions for Portage Biotech and 0 mentions for Calisa Acquisition. Portage Biotech's average media sentiment score of 0.00 equaled Calisa Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Portage Biotech	Neutral
Calisa Acquisition	Neutral

13.4% of Portage Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Calisa Acquisition has lower revenue, but higher earnings than Portage Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	$100K	23.28	-$38.63M	-$8.18	N/A
Calisa Acquisition	N/A	N/A	N/A	N/A	N/A

Portage Biotech currently has a consensus price target of $0.25, indicating a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Portage Biotech is more favorable than Calisa Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Calisa Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Portage Biotech beats Calisa Acquisition on 5 of the 5 factors compared between the two stocks.

How does Portage Biotech compare to Core Scientific?

Portage Biotech (NASDAQ:ALP) and Core Scientific (NASDAQ:CORZZ) are both technology companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

13.4% of Portage Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Portage Biotech currently has a consensus target price of $0.25, indicating a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Portage Biotech is more favorable than Core Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Core Scientific	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Portage Biotech had 2 more articles in the media than Core Scientific. MarketBeat recorded 2 mentions for Portage Biotech and 0 mentions for Core Scientific. Portage Biotech's average media sentiment score of 0.00 equaled Core Scientific'saverage media sentiment score.

Company	Overall Sentiment
Portage Biotech	Neutral
Core Scientific	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Core Scientific	N/A	N/A	N/A

Core Scientific has higher revenue and earnings than Portage Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	$100K	23.28	-$38.63M	-$8.18	N/A
Core Scientific	$440.31M	N/A	N/A	N/A	N/A

Summary

Portage Biotech beats Core Scientific on 4 of the 5 factors compared between the two stocks.

How does Portage Biotech compare to Core Scientific?

Portage Biotech (NASDAQ:ALP) and Core Scientific (NASDAQ:CORZW) are both technology companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Core Scientific	N/A	N/A	N/A

13.4% of Portage Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Core Scientific has higher revenue and earnings than Portage Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	$100K	23.28	-$38.63M	-$8.18	N/A
Core Scientific	$440.31M	N/A	N/A	N/A	N/A

Portage Biotech presently has a consensus price target of $0.25, indicating a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Portage Biotech is more favorable than Core Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Core Scientific	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Portage Biotech	Neutral
Core Scientific	Neutral

Summary

Portage Biotech beats Core Scientific on 4 of the 5 factors compared between the two stocks.

How does Portage Biotech compare to D. Boral ARC Acquisition I?

D. Boral ARC Acquisition I (NASDAQ:BCARW) and Portage Biotech (NASDAQ:ALP) are both technology companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, Portage Biotech had 2 more articles in the media than D. Boral ARC Acquisition I. MarketBeat recorded 2 mentions for Portage Biotech and 0 mentions for D. Boral ARC Acquisition I. D. Boral ARC Acquisition I's average media sentiment score of 0.00 equaled Portage Biotech'saverage media sentiment score.

Company	Overall Sentiment
D. Boral ARC Acquisition I	Neutral
Portage Biotech	Neutral

Company	Net Margins	Return on Equity	Return on Assets
D. Boral ARC Acquisition I	N/A	N/A	N/A
Portage Biotech	N/A	N/A	N/A

13.4% of Portage Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Portage Biotech has a consensus price target of $0.25, suggesting a potential upside of 152.02%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Portage Biotech is more favorable than D. Boral ARC Acquisition I.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
D. Boral ARC Acquisition I	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Portage Biotech	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

D. Boral ARC Acquisition I has higher earnings, but lower revenue than Portage Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
D. Boral ARC Acquisition I	N/A	N/A	N/A	N/A	N/A
Portage Biotech	$100K	23.28	-$38.63M	-$8.18	N/A

Summary

Portage Biotech beats D. Boral ARC Acquisition I on 5 of the 5 factors compared between the two stocks.

Get Portage Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALP vs. The Competition

Export

Metric	Portage Biotech	IT Services Industry	Technology Sector	NASDAQ Exchange
Market Cap	$2.33M	$10.92B	$29.95B	$12.89B
Dividend Yield	N/A	2.78%	2.73%	9.13%
P/E Ratio	-0.01	14.31	76.19	25.45
Price / Sales	23.28	66.12	593.83	100.83
Price / Cash	N/A	43.34	46.84	35.62
Price / Book	0.35	8.28	7.83	6.39
Net Income	-$38.63M	$271.39M	$704.49M	$358.69M
7 Day Performance	N/A	-0.05%	-0.80%	0.22%
1 Month Performance	N/A	-0.81%	-1.46%	-0.10%
1 Year Performance	N/A	31.97%	186.44%	14.04%

Portage Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALP Portage Biotech	1.6939 of 5 stars	$0.10 flat	$0.25 +152.0%	N/A	$2.33M	$100K	N/A	6	Gap Down
BRUN Boost Run	2.6915 of 5 stars	$18.19 -2.7%	$45.00 +147.4%	N/A	$0.00	$56.42M	N/A	N/A	Gap Down
ALIS Calisa Acquisition	N/A	$10.22 flat	N/A	N/A	$0.00	N/A	N/A	3
CORZZ Core Scientific	N/A	$17.53 -2.2%	N/A	+30.8%	$0.00	$440.31M	N/A	200	Gap Down
CORZW Core Scientific	N/A	$10.72 -5.5%	N/A	+49.4%	$0.00	$440.31M	N/A	118	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALP) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Portage Biotech (ALP) Competitors

ALP vs. BRUN, ALIS, CORZZ, CORZW, and BCARW

How does Portage Biotech compare to Boost Run?

Summary

How does Portage Biotech compare to Calisa Acquisition?

Summary

How does Portage Biotech compare to Core Scientific?

Summary

How does Portage Biotech compare to Core Scientific?

Summary

How does Portage Biotech compare to D. Boral ARC Acquisition I?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALP vs. The Competition

Portage Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Portage Biotech (ALP) Competitors

ALP vs. BRUN, ALIS, CORZZ, CORZW, and BCARW

How does Portage Biotech compare to Boost Run?

Do analysts prefer BRUN or ALP?

Is BRUN or ALP more profitable?

Does the media refer more to BRUN or ALP?

Which has preferable earnings & valuation, BRUN or ALP?

Do insiders & institutionals have more ownership in BRUN or ALP?

Summary

How does Portage Biotech compare to Calisa Acquisition?

Is ALP or ALIS more profitable?

Does the media favor ALP or ALIS?

Do insiders and institutionals believe in ALP or ALIS?

Which has higher earnings and valuation, ALP or ALIS?

Do analysts recommend ALP or ALIS?

Summary

How does Portage Biotech compare to Core Scientific?

Do insiders & institutionals believe in ALP or CORZZ?

Do analysts rate ALP or CORZZ?

Does the media prefer ALP or CORZZ?

Is ALP or CORZZ more profitable?

Which has higher valuation & earnings, ALP or CORZZ?

Summary

How does Portage Biotech compare to Core Scientific?

Is ALP or CORZW more profitable?

Do insiders and institutionals believe in ALP or CORZW?

Which has preferable earnings and valuation, ALP or CORZW?

Do analysts rate ALP or CORZW?

Does the media refer more to ALP or CORZW?

Summary

How does Portage Biotech compare to D. Boral ARC Acquisition I?

Does the media favor BCARW or ALP?

Is BCARW or ALP more profitable?

Do insiders & institutionals hold more shares of BCARW or ALP?

Do analysts rate BCARW or ALP?

Which has preferable earnings and valuation, BCARW or ALP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALP vs. The Competition

Portage Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools